Literature DB >> 14616418

Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

N R Labiris1, M B Dolovich.   

Abstract

As the end organ for the treatment of local diseases or as the route of administration for systemic therapies, the lung is a very attractive target for drug delivery. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications. As a major port of entry, the lung has evolved to prevent the invasion of unwanted airborne particles from entering into the body. Airway geometry, humidity, mucociliary clearance and alveolar macrophages play a vital role in maintaining the sterility of the lung and consequently are barriers to the therapeutic effectiveness of inhaled medications. In addition, a drug's efficacy may be affected by where in the respiratory tract it is deposited, its delivered dose and the disease it may be trying to treat.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616418      PMCID: PMC1884307          DOI: 10.1046/j.1365-2125.2003.01892.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  53 in total

1.  Allometric relationships of cell numbers and size in the mammalian lung.

Authors:  K C Stone; R R Mercer; P Gehr; B Stockstill; J D Crapo
Journal:  Am J Respir Cell Mol Biol       Date:  1992-02       Impact factor: 6.914

2.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction.

Authors:  P Zanen; L T Go; J W Lammers
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

3.  Drug delivery via the respiratory tract.

Authors:  P R Byron; J S Patton
Journal:  J Aerosol Med       Date:  1994

4.  Regional deposition of aerosolized pentamidine. Effects of body position and breathing pattern.

Authors:  M I Baskin; A G Abd; J S Ilowite
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

5.  Theoretic analysis of sites of aerosol deposition in the human lung.

Authors:  T R Gerrity; C S Garrard; D B Yeates
Journal:  Chest       Date:  1981-12       Impact factor: 9.410

6.  Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols.

Authors:  D L Swift
Journal:  Am Rev Respir Dis       Date:  1980-11

7.  Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration.

Authors:  R S Baltimore; C D Christie; G J Smith
Journal:  Am Rev Respir Dis       Date:  1989-12

8.  Intrapulmonary administration of insulin to healthy volunteers.

Authors:  J H Jendle; B E Karlberg
Journal:  J Intern Med       Date:  1996-08       Impact factor: 8.989

9.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

Authors:  J S Ilowite; J D Gorvoy; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1987-12

10.  Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats.

Authors:  A Yamamoto; S Umemori; S Muranishi
Journal:  J Pharm Pharmacol       Date:  1994-01       Impact factor: 3.765

View more
  212 in total

Review 1.  Exogenous surfactant: intubated present, nebulized future?

Authors:  Shetal Shah
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

2.  Targeted delivery of liquid microvolumes into the lung.

Authors:  Jinho Kim; John D O'Neill; N Valerio Dorrello; Matthew Bacchetta; Gordana Vunjak-Novakovic
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

3.  Feasibility of tissue plasminogen activator formulated for pulmonary delivery.

Authors:  John S Dunn; Rajiv Nayar; Jackie Campos; Brooks M Hybertson; Yue Zhou; Mark Cornell Manning; John E Repine; Kathleen A Stringer
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

4.  Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer.

Authors:  Nkechi Ichite; Mahavir Chougule; Apurva R Patel; Tanise Jackson; Stephen Safe; Mandip Singh
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

5.  Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.

Authors:  Karishma S Kaushik; Jake Stolhandske; Orrin Shindell; Hugh D Smyth; Vernita D Gordon
Journal:  NPJ Biofilms Microbiomes       Date:  2016-05-25       Impact factor: 7.290

6.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

7.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

Review 8.  Organ-on-a-chip platforms for studying drug delivery systems.

Authors:  Nupura S Bhise; João Ribas; Vijayan Manoharan; Yu Shrike Zhang; Alessandro Polini; Solange Massa; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

9.  In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery.

Authors:  Noor Hafizah Arbain; Norazlinaliza Salim; Hamid Reza Fard Masoumi; Tin Wui Wong; Mahiran Basri; Mohd Basyaruddin Abdul Rahman
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

10.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.